Zydus Lifesciences has received an Establishment Inspection Report from the USFDA for its Baddi unit. The inspection, held between 4–13 August 2025, resulted in a Voluntary Action Indicated (VAI) status, confirming the plant’s compliance with US regulatory standards.
Source: Zydus Lifesciences Limited Press Release (NSE Exchange Filings) | Published on Oct 29, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Zydus Lifesciences Limited and its official news filing (NSE Exchange Filings), the company confirmed that the United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for its Baddi manufacturing facility in Himachal Pradesh.
The inspection took place from 4 August 2025 to 13 August 2025, after which the facility received a VAI classification, indicating that observations made during the audit do not require further regulatory action. This classification supports Zydus Lifesciences’ ongoing manufacturing and export operations for regulated markets.
Also read: Dr Reddy’s Gets Non-Compliance Notice from Canada
Zydus Lifesciences received a USFDA EIR for its Baddi plant.
The inspection was conducted from 4 August to 13 August 2025.
The facility has been classified as Voluntary Action Indicated (VAI).
The inspection at Zydus Lifesciences’ Baddi site was conducted to evaluate compliance with current Good Manufacturing Practices (cGMP). The USFDA issued the Establishment Inspection Report after completing its review of post-inspection responses.
The Voluntary Action Indicated status reflects that the inspection identified only minor observations. Such facilities can continue normal operations without additional USFDA enforcement action.
Zydus Lifesciences operates multiple USFDA-approved plants in India, including facilities in Ahmedabad, Vadodara, and Baddi. The company manufactures finished dosage formulations, active pharmaceutical ingredients, and biologics for domestic and international markets.
Zydus Lifesciences Limited, headquartered in Ahmedabad, Gujarat, is a diversified pharmaceutical organisation engaged in research, manufacturing, and marketing of therapeutic products. Its portfolio covers cardiovascular, gastrointestinal, and oncology segments.
The receipt of the EIR marks a regulatory step for Zydus Lifesciences as it maintains compliance across all its USFDA-inspected facilities. The company continues to serve global markets through quality-compliant manufacturing operations.
Parameter | Detail |
Company | Zydus Lifesciences Limited |
Facility Location | Baddi, Himachal Pradesh, India |
Regulatory Authority | United States Food and Drug Administration (USFDA) |
Inspection Period | 4 August 2025 – 13 August 2025 |
Report Type | Establishment Inspection Report (EIR) |
Classification | Voluntary Action Indicated (VAI) |
Focus Area | cGMP Compliance for Pharmaceutical Manufacturing |
The Baddi manufacturing facility plays a key role in producing oral solid dosage forms and sterile products for export to the United States. The receipt of the EIR enables Zydus Lifesciences to maintain uninterrupted manufacturing and distribution of approved products.
The company continues to follow stringent quality-control procedures across its network of plants. Its regulatory track record includes multiple facilities cleared by agencies such as the USFDA, EMA, and MHRA.
As of 29 October 2025, 15:30 IST PM, Zydus Lifesciences' share price on the National Stock Exchange (NSE) was ₹1,002.00, up ₹0.75 (0.07 %) from the previous close of ₹1,001.25.
Also Read: Ola Electric Receives CCPA Investigation Report and Hearing Date
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading